Pfizer Boosts Rare Disease Franchise through Bamboo Therapeutics Acquisition

By Jasmine Kalsi

Pharma Deals Review: Vol 2016 Issue 8 (Table of Contents)

Published: 17 Aug-2016

DOI: 10.3833/pdr.v2016.i8.2184     ISSN: 1756-7874

Section: Mergers & Acquisitions



Fortifying its orphan disease portfolio with gene therapies, Pfizer acquired US based private biotech Bamboo Therapeutics for a consolidated sum of up to US$645 M, including US$150 M upfront and US$495 M in contingent milestones...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details